The global renin inhibitors market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing prevalence of hypertension and its associated complications such as heart disease, stroke, and kidney failure. Renin inhibitors are used for the treatment of hypertension in patients with chronic kidney disease (CKD) or diabetes mellitus type 2 (DM2). Renin inhibitors are also used for the treatment of congestive heart failure (CHF) in patients with CKD or DM2. Renin inhibitors are classified into two types: 150mg/tablet and 300mg/tablet. The 150mg/tablet segment accounted for a share of over 50% in 2018 owing to its lower price compared to 300mg/tablet segment which has higher efficacy but higher price per tablet. The application segments include age below 45 years, age 455 years, age 565 years, and above 65 years. Age below 45 accounted for over 50% share in 2018 due to high prevalence rates among this population group as well as their increased risk factors such as obesity and sedentary lifestyle which lead to an increased risk of developing hypertension earlier than other population groups.
- The Renin-Inhibitors market is expected to grow at a CAGR of 5.5% from 2017 to 2022.
- The increasing prevalence of chronic kidney disease and hypertension in the elderly population is expected to drive the growth of the Renin-Inhibitors market.
- The increasing number of cardiovascular diseases, which are major causes for renal failure, is also driving the growth of this market.
- Increasing awareness about lifestyle changes and their impact on health conditions such as hypertension and diabetes will also drive the growth of this market.
- Increasing focus on preventive healthcare by governments across various regions will also fuel the growth of this market.
Industry Growth Insights published a new data on “Renin-Inhibitors Market”. The research report is titled “Renin-Inhibitors Market research by Types (150mg/Tablet, 300mg/Tablet), By Applications (Age below 45, Age 45-55, Age 55-65, Age above 65), By Players/Companies Novartis, Noden Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Renin-Inhibitors Market Research Report
By Type
150mg/Tablet, 300mg/Tablet
By Application
Age below 45, Age 45-55, Age 55-65, Age above 65
By Companies
Novartis, Noden Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Renin-Inhibitors Market Report Segments:
The global Renin-Inhibitors market is segmented on the basis of:
Types
150mg/Tablet, 300mg/Tablet
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Age below 45, Age 45-55, Age 55-65, Age above 65
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Noden Pharma
Highlights of The Renin-Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 150mg/Tablet
- 300mg/Tablet
- By Application:
- Age below 45
- Age 45-55
- Age 55-65
- Age above 65
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Renin-Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Renin-inhibitors are medications that block the action of renin, a hormone that is responsible for regulating blood pressure. Renin-inhibitors can be used to treat high blood pressure, heart failure, and other conditions.
Some of the major companies in the renin-inhibitors market are Novartis, Noden Pharma.
The renin-inhibitors market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Renin-Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Renin-Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Renin-Inhibitors Market - Supply Chain
4.5. Global Renin-Inhibitors Market Forecast
4.5.1. Renin-Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Renin-Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Renin-Inhibitors Market Absolute $ Opportunity
5. Global Renin-Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Renin-Inhibitors Market Size and Volume Forecast by Type
5.3.1. 150mg/Tablet
5.3.2. 300mg/Tablet
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Renin-Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Renin-Inhibitors Market Size and Volume Forecast by Application
6.3.1. Age below 45
6.3.2. Age 45-55
6.3.3. Age 55-65
6.3.4. Age above 65
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Renin-Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Renin-Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Renin-Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Renin-Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Renin-Inhibitors Demand Share Forecast, 2019-2026
9. North America Renin-Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Renin-Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Renin-Inhibitors Market Size and Volume Forecast by Application
9.4.1. Age below 45
9.4.2. Age 45-55
9.4.3. Age 55-65
9.4.4. Age above 65
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Renin-Inhibitors Market Size and Volume Forecast by Type
9.7.1. 150mg/Tablet
9.7.2. 300mg/Tablet
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Renin-Inhibitors Demand Share Forecast, 2019-2026
10. Latin America Renin-Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Renin-Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Renin-Inhibitors Market Size and Volume Forecast by Application
10.4.1. Age below 45
10.4.2. Age 45-55
10.4.3. Age 55-65
10.4.4. Age above 65
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Renin-Inhibitors Market Size and Volume Forecast by Type
10.7.1. 150mg/Tablet
10.7.2. 300mg/Tablet
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Renin-Inhibitors Demand Share Forecast, 2019-2026
11. Europe Renin-Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Renin-Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Renin-Inhibitors Market Size and Volume Forecast by Application
11.4.1. Age below 45
11.4.2. Age 45-55
11.4.3. Age 55-65
11.4.4. Age above 65
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Renin-Inhibitors Market Size and Volume Forecast by Type
11.7.1. 150mg/Tablet
11.7.2. 300mg/Tablet
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Renin-Inhibitors Demand Share, 2019-2026
12. Asia Pacific Renin-Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Renin-Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Renin-Inhibitors Market Size and Volume Forecast by Application
12.4.1. Age below 45
12.4.2. Age 45-55
12.4.3. Age 55-65
12.4.4. Age above 65
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Renin-Inhibitors Market Size and Volume Forecast by Type
12.7.1. 150mg/Tablet
12.7.2. 300mg/Tablet
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Renin-Inhibitors Demand Share, 2019-2026
13. Middle East & Africa Renin-Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Renin-Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Renin-Inhibitors Market Size and Volume Forecast by Application
13.4.1. Age below 45
13.4.2. Age 45-55
13.4.3. Age 55-65
13.4.4. Age above 65
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Renin-Inhibitors Market Size and Volume Forecast by Type
13.7.1. 150mg/Tablet
13.7.2. 300mg/Tablet
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Renin-Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Renin-Inhibitors Market: Market Share Analysis
14.2. Renin-Inhibitors Distributors and Customers
14.3. Renin-Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Noden Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook